RecruitingNot ApplicableNCT06960291

Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada

Sponsor

University of Calgary

Enrollment

740 participants

Start Date

Mar 11, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Cancers Cancer Colon Cancer Breast Cancers Prostate Cancers

Summary

EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-trained exercise specialists in Canada, outside of the research setting. Considering the negative impact cancer and its treatments have on fitness and physical activity levels, community-based efforts towards improving access, uptake and maintenance of exercise programming are needed. This study will evaluate the benefits of a community-based or online EXCEL exercise program for people living with and beyond cancer across Canada, using a streamlined intake process compared to the original EXCEL Study (HREBA.CC-20-0098, NCT04478851). This 8 to 12-week program (intervention) will be delivered in-person or over virtual platform. It includes twice weekly supervised exercise classes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how to better support cancer patients in staying active through exercise programs. Researchers are working to make the EXCEL exercise oncology program more widely and sustainably available to people with cancer across Canada. The goal is to understand what helps (or prevents) these programs from reaching more patients. **You may be eligible if...** - You have been diagnosed with cancer (any type) at any stage - You are 18 or older - You are able to do at least light physical activity - You are currently undergoing cancer treatment, or finished treatment within the past 3 years — or if it's been longer, your doctor referred you because you have ongoing side effects that exercise may help - You can communicate in English or French **You may NOT be eligible if...** - You have never had a cancer diagnosis - You are under 18 - You are unable to do any level of exercise - You finished cancer treatment more than 3 years ago and don't have ongoing side effects - You cannot read or write in English - You don't have internet or computer access (for online programs) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALGroup Exercise Classes

Participants will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting, twice weekly for a 8-12-week period (duration of intervention depends on scheduling logistics for the coordinating hubs and their spokes sites). The exercise sessions will be conducted in groups with a ratio of up to 15 participants per instructor. The program follows exercise progression principles (i.e., frequency, intensity, time, type, overload and progression) over the 8-12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits.

Locations(5)

University of Calgary

Calgary, Alberta, Canada

University of British Columbia

Vancouver, British Columbia, Canada

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

University of Toronto

Toronto, Ontario, Canada

Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06960291

Related Trials

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT055881411 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations